All Gossamer Bio wants is to go public and fast, but the start and end of the US government shutdown has thrown its IPO plans into disarray, prompting the San Diego-based biotech to once again shift gear.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,